The center currently accepts only fresh brain donations from the general population, and does not bank Alzheimer's brains or brains with unspecified dementia. Normal controls are welcome, as are ...
APOE4 was originally studied in the context of blood lipids and cardiovascular disease and first characterized at the protein level as one of three inherited ApoE isoforms with unique ...
More Antibodies take aim at seeded propagation. New data ties tangle location to deficits in specific cognitive domains. Three first-in-human studies for antibodies targeting different parts of tau ...
Amyloid immunotherapies are here, but inflammaging remains a powerful driver of neurodegenerative disease. Neuroinflammation is a rich, but thus far quite elusive, source of new drug targets. Some ...
In a small, open-label trial in people with mild to moderate, dominantly inherited Alzheimer’s disease (DIAD), the tau immunotherapy etalanetug almost abolished markers of neurofibrillary tangles in ...
More than two decades have passed since William Pardridge of the University of California, Los Angeles, used the analogy of a Trojan horse to describe molecular transport shuttles that can sneak ...
On November 24, Novo Nordisk announced that the GLP-1 mimetic semaglutide had failed to slow progression of Alzheimer’s disease in two Phase 3 trials. Even though the cat was out of the bag, ...
For all the reams of previous research on APOE, scientists are still turning up fresh insights on how its alleles affect biology and disease risk. At the 18th Clinical Trials on Alzheimer’s Disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback